Burn News and Research

RSS

Rib-X commences Phase 2b trial to assess delafloxacin, linezolid, vancomycin for treatment of ABSSSI

Rib-X Pharmaceuticals, an antibiotics company with a broad development-stage pipeline, today announced the initiation of a Phase 2b clinical trial to evaluate delafloxacin, linezolid and vancomycin for the treatment of acute bacterial skin and skin structure infections, including infections caused by methicillin-resistant Staphylococcus aureus.

8 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

A low cost, nanometer-sized drug to treat chronic wounds, such as diabetic foot ulcers or burns, has been developed by a group of scientists from the Hebrew University of Jerusalem, Harvard Medical School and others in the U.S. and Japan.

8 Feb 2011

Some House Republicans see health law as prime spot for deep budget cuts

Even as GOP lawmakers advance their strategies, Dems see a plan of their own — they plan to cast Republicans as trying to take away patients' rights. Meanwhile, physicians take to the Hill to press for medical liability reforms, with lots of lobbying money streaming in.

8 Feb 2011

Scientists develop low cost, nanometer-sized drug to treat chronic wounds

7 Feb 2011

Safe Kids USA reminds parents to keep children safe from burn injuries

Each year 465 children ages 14 and under die due to unintentional fire or burn related injuries, with children ages 3 and younger at the greatest risk, according to the Centers for Disease Control.

5 Feb 2011

Pediatric neurosurgery patient named Grand Marshal of 2011 Go the Distance fundraising event

A quiet, peaceful evening last summer quickly turned into a nightmare for parents Amanda and Bryan Tormey when they were awoken by sounds of their three year-old son, Nathan, stirring in his bed. When they checked on him, the cause of Nathan's restlessness became frighteningly evident; Nathan was in the midst of massive seizure that would ultimately incapacitate him for several hours.

4 Feb 2011

New 'skin gun' treats burns with stem cells

A revolutionary new "skin gun" developed to treat burns could be the latest in a remarkable string of stem-cell breakthroughs poised to change the face of medicine, says Emerging Healthcare Solutions President and CEO Cindy Morrissey.

4 Feb 2011

Study: Facelift surgery improves appearance and quality of life in most patients

Patients who have undergone a facelift rate themselves as looking an average of 12 years younger after surgery, according to a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

2 Feb 2011

New study reports migraine surgery eliminates headache in nearly 30% of patients

Surgery to "deactivate" migraine headaches produces lasting good results, with nearly 90 percent of patients having at least partial relief at five years' follow-up, reports a study in the February issue of Plastic and Reconstructive Surgery, the official medical journal of the American Society of Plastic Surgeons.

2 Feb 2011

Researchers invent paper microfluidic device for rapid medical diagnostics, chemical analysis

Researchers have invented a technique that uses inexpensive paper to make "microfluidic" devices for rapid medical diagnostics and chemical analysis.

27 Jan 2011

Ligand announces acquisition of CyDex Pharmaceuticals

Ligand Pharmaceuticals Incorporated today announced it has acquired privately held CyDex Pharmaceuticals, for a combination of cash and contingent payments.

26 Jan 2011

Massive drinks mean massive calories

When you're ordering the new Starbucks "trenta" you're not only getting a massive drink (31 ounces) but massive calories (up to 600) - with the potential to pack on more than 60 extra pounds in one year.

25 Jan 2011

California jury awards $2.2 million in defective laparoscopic device case

Encision Inc. – A California jury awarded $2.2 million to a patient in a personal injury, product liability, defective laparoscopic device case against a competing medical device company; as reported in the Daily Journal.

25 Jan 2011

UMB enters license agreement with Bali BioSciences for new strategy to combat sepsis, HIV/AIDS

The University of Maryland, Baltimore's (UMB) Office of Technology Transfer has completed a license agreement with Bali BioSciences LLC, an early-stage company pursuing an unusual, yet clever, strategy to combat disease.

20 Jan 2011

UC San Diego receives two grants to expand TREDS program for older drivers

A team of experts from the School's Trauma Epidemiology and Injury Prevention Research Center has received two grants to expand the program, which focuses on interventions to assist older drivers who may be at risk for a crash due to age-related health impairments.

19 Jan 2011

Wisepower acquires Unidym

Arrowhead Research Corporation today announced that its Unidym, Inc. subsidiary has been acquired by Wisepower Co., Ltd., a publicly-traded, Seoul, Korea-based electronics company. Upfront consideration to Unidym shareholders consists of Wisepower stock and convertible bonds valued at US $5,000,000 with certain restrictions as to timing of stock sales.

18 Jan 2011

BioCryst reports positive results from peramivir Phase 3 study in influenza

BioCryst Pharmaceuticals, Inc. today announced top-line results from one of its two Phase 3 studies of intravenous (i.v.) peramivir for the treatment of patients hospitalized with influenza, and provided an update regarding its peramivir program.

13 Jan 2011

Obesity in children today may contribute to 2-5 year decline in life expectancy

For the first time in history, the next generation will not live longer, or even as long, as their parents. "Diseases such as Type II diabetes, high blood pressure, heart conditions and joint deterioration - what were once considered 'adult' diseases - are regularly being diagnosed in children, due to the prevalence of obesity," said Jessica Bartfield, MD, internal medicine and medical weight-loss specialist at Gottlieb Memorial Hospital, part of the Loyola University Health System.

13 Jan 2011

FDA accepts to review Fibrocell Science's azficel-T drug

Fibrocell Science, a biotechnology company focused on the development of autologous cell therapies for aesthetic, medical and scientific applications, announced today that the U.S. Food & Drug Administration has accepted for review the Company's complete response submission for azficel-T, proposed brand name laViv, for the treatment of moderate to severe nasolabial folds and wrinkles.

12 Jan 2011

Slowing engines of mitochondria could extend life

In making your pro-longevity resolutions, like drinking more red wine and maintaining a vibrant social network, here's one you likely forgot: dialing down your mitochondria. It turns out that slowing the engines of these tiny cellular factories could extend your life-an observation relevant not only to aging research but to our understanding of how cells communicate with each another.

10 Jan 2011